JP6091811B2 - ピラゾール化合物及びその医薬用途 - Google Patents

ピラゾール化合物及びその医薬用途 Download PDF

Info

Publication number
JP6091811B2
JP6091811B2 JP2012190429A JP2012190429A JP6091811B2 JP 6091811 B2 JP6091811 B2 JP 6091811B2 JP 2012190429 A JP2012190429 A JP 2012190429A JP 2012190429 A JP2012190429 A JP 2012190429A JP 6091811 B2 JP6091811 B2 JP 6091811B2
Authority
JP
Japan
Prior art keywords
group
alkyl group
compound
alkoxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012190429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013063968A (ja
JP2013063968A5 (https=
Inventor
智也 三浦
智也 三浦
洋介 生越
洋介 生越
和人 上山
和人 上山
大 元田
大 元田
俊彦 岩山
俊彦 岩山
孝一 須澤
孝一 須澤
弘将 長森
弘将 長森
弘資 上野
弘資 上野
高橋　明彦
明彦 高橋
和幸 杉本
和幸 杉本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to JP2012190429A priority Critical patent/JP6091811B2/ja
Publication of JP2013063968A publication Critical patent/JP2013063968A/ja
Publication of JP2013063968A5 publication Critical patent/JP2013063968A5/ja
Application granted granted Critical
Publication of JP6091811B2 publication Critical patent/JP6091811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012190429A 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途 Active JP6091811B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012190429A JP6091811B2 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011188121 2011-08-31
JP2011188121 2011-08-31
JP2012190429A JP6091811B2 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017021326A Division JP2017082005A (ja) 2011-08-31 2017-02-08 ピラゾール化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2013063968A JP2013063968A (ja) 2013-04-11
JP2013063968A5 JP2013063968A5 (https=) 2015-10-15
JP6091811B2 true JP6091811B2 (ja) 2017-03-08

Family

ID=47756400

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012190429A Active JP6091811B2 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途
JP2017021326A Ceased JP2017082005A (ja) 2011-08-31 2017-02-08 ピラゾール化合物及びその医薬用途
JP2018088578A Ceased JP2018115216A (ja) 2011-08-31 2018-05-02 ピラゾール化合物及びその医薬用途
JP2020081097A Ceased JP2020125348A (ja) 2011-08-31 2020-05-01 ピラゾール化合物及びその医薬用途
JP2023075967A Ceased JP2023087032A (ja) 2011-08-31 2023-05-02 ピラゾール化合物及びその医薬用途
JP2025000092A Withdrawn JP2025039641A (ja) 2011-08-31 2025-01-06 ピラゾール化合物及びその医薬用途

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017021326A Ceased JP2017082005A (ja) 2011-08-31 2017-02-08 ピラゾール化合物及びその医薬用途
JP2018088578A Ceased JP2018115216A (ja) 2011-08-31 2018-05-02 ピラゾール化合物及びその医薬用途
JP2020081097A Ceased JP2020125348A (ja) 2011-08-31 2020-05-01 ピラゾール化合物及びその医薬用途
JP2023075967A Ceased JP2023087032A (ja) 2011-08-31 2023-05-02 ピラゾール化合物及びその医薬用途
JP2025000092A Withdrawn JP2025039641A (ja) 2011-08-31 2025-01-06 ピラゾール化合物及びその医薬用途

Country Status (28)

Country Link
US (5) US8846746B2 (https=)
EP (4) EP3524599A1 (https=)
JP (6) JP6091811B2 (https=)
KR (1) KR101989203B1 (https=)
CN (1) CN103917535B (https=)
AR (2) AR087701A1 (https=)
AU (1) AU2012302723B2 (https=)
BR (1) BR112014004651B1 (https=)
CA (1) CA2845127C (https=)
CL (1) CL2014000490A1 (https=)
CO (1) CO6890098A2 (https=)
CY (1) CY1121631T1 (https=)
DK (1) DK3199533T3 (https=)
HK (1) HK1202290A1 (https=)
IL (1) IL230763A (https=)
MX (1) MX359825B (https=)
MY (1) MY172422A (https=)
PE (1) PE20142343A1 (https=)
PH (1) PH12014500444A1 (https=)
PL (1) PL3199533T3 (https=)
RS (1) RS58870B1 (https=)
RU (1) RU2617678C2 (https=)
SG (1) SG11201400244YA (https=)
SI (1) SI3199533T1 (https=)
SM (1) SMT201900292T1 (https=)
TW (1) TWI549949B (https=)
WO (1) WO2013031922A1 (https=)
ZA (1) ZA201401071B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017082005A (ja) * 2011-08-31 2017-05-18 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JP5663699B2 (ja) 2012-05-07 2015-02-04 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
MY176162A (en) * 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
US9334307B2 (en) 2013-05-08 2016-05-10 The University Of Houston System Targeting the EGFR-SGLT1 interaction for cancer therapy
CN105294703B (zh) * 2015-10-23 2018-01-23 西安近代化学研究所 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法
BR112019002733A2 (pt) 2016-08-11 2019-05-14 Bayer Cropscience Ag derivados de pirazolinil substituídos, processos para sua preparação e seu uso como herbicidas e/ou reguladores de crescimento da planta
JP6994498B2 (ja) 2016-08-15 2022-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ３－アミノ－１－（２，６－二置換フェニル）ピラゾール類を調製する方法
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
US20230119894A1 (en) * 2019-09-04 2023-04-20 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
CA3175131A1 (en) 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure
WO2025249555A1 (en) * 2024-05-31 2025-12-04 Japan Tobacco Inc. Method for treating or preventing hypertrophic cardiomyopathy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
RU2356906C2 (ru) * 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AP2007003979A0 (en) 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
EP1951678A1 (en) 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
EP2079728B1 (en) * 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
JP4994295B2 (ja) 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010222298A (ja) * 2009-03-24 2010-10-07 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
WO2012002527A1 (ja) 2010-07-02 2012-01-05 あすか製薬株式会社 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017082005A (ja) * 2011-08-31 2017-05-18 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途
JP2018115216A (ja) * 2011-08-31 2018-07-26 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途

Also Published As

Publication number Publication date
PH12014500444A1 (en) 2017-04-07
RS58870B1 (sr) 2019-08-30
CO6890098A2 (es) 2014-03-10
WO2013031922A1 (ja) 2013-03-07
US8846746B2 (en) 2014-09-30
US20150183763A1 (en) 2015-07-02
CL2014000490A1 (es) 2014-08-22
EP3199533B1 (en) 2019-02-27
JP2023087032A (ja) 2023-06-22
JP2018115216A (ja) 2018-07-26
SG11201400244YA (en) 2014-10-30
BR112014004651B1 (pt) 2021-08-31
US20230348438A1 (en) 2023-11-02
SI3199533T1 (sl) 2019-06-28
EP4656638A3 (en) 2026-01-28
CN103917535A (zh) 2014-07-09
CY1121631T1 (el) 2020-07-31
RU2617678C2 (ru) 2017-04-26
BR112014004651A2 (pt) 2017-03-28
NZ620977A (en) 2016-02-26
US20200317644A1 (en) 2020-10-08
IL230763A (en) 2016-10-31
MX359825B (es) 2018-10-10
EP2784074A1 (en) 2014-10-01
AR123441A2 (es) 2022-11-30
SMT201900292T1 (it) 2019-07-11
PE20142343A1 (es) 2015-01-29
CA2845127C (en) 2020-03-10
KR101989203B1 (ko) 2019-06-13
CN103917535B (zh) 2015-06-24
JP2020125348A (ja) 2020-08-20
EP4656638A2 (en) 2025-12-03
AU2012302723B2 (en) 2016-08-11
TW201321372A (zh) 2013-06-01
PL3199533T3 (pl) 2019-09-30
IL230763A0 (en) 2014-03-31
EP2784074A4 (en) 2015-06-03
US20180346449A1 (en) 2018-12-06
ZA201401071B (en) 2016-10-26
HK1202290A1 (en) 2015-09-25
MY172422A (en) 2019-11-25
JP2013063968A (ja) 2013-04-11
US20130085132A1 (en) 2013-04-04
KR20140062048A (ko) 2014-05-22
EP3199533A1 (en) 2017-08-02
CA2845127A1 (en) 2013-03-07
MX2014002552A (es) 2014-04-25
JP2017082005A (ja) 2017-05-18
DK3199533T3 (da) 2019-05-20
TWI549949B (zh) 2016-09-21
EP3524599A1 (en) 2019-08-14
RU2014112048A (ru) 2015-10-10
AU2012302723A1 (en) 2014-02-27
JP2025039641A (ja) 2025-03-21
AR087701A1 (es) 2014-04-09

Similar Documents

Publication Publication Date Title
JP6091811B2 (ja) ピラゾール化合物及びその医薬用途
KR101088247B1 (ko) 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
CN101309917B (zh) 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EA021126B1 (ru) Замещенные изохинолиноны и хинализолиноны
CN102341395A (zh) 作为抗炎剂的3H-咪唑并[4，5-c]吡啶-6-甲酰胺
TWI439452B (zh) 吡咯烷化合物（二）
EP1724259A1 (en) 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension
KR101378260B1 (ko) 세로토닌 및 노르에피네프린 재흡수 억제제
HK1242309A1 (en) Pyrazole compound and pharmaceutical use thereof
HK1242309B (en) Pyrazole compound and pharmaceutical use thereof
NZ620977B2 (en) Pyrazole compound and use thereof for medical purposes
AU2018211735A1 (en) Phenyldifluoromethyl-substituted prolinamide compound
CN106496132A (zh) N‑(4‑取代苯基)‑2‑取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150828

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170208

R150 Certificate of patent or registration of utility model

Ref document number: 6091811

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350